0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Journal Articles

in Prostate Cancer
 21-40 of 300 Articles
JAMA Internal Medicine | 
Original Investigation | 
Victoria L. Tang, MD, MAS; Ying Shi, PhD; Kathy Fung, MS; et al.
JAMA Intern Med. 2016;176(5):654-661. doi:10.1001/jamainternmed.2016.0695.
Includes: CME, Supplemental Content

JAMA Internal Medicine | 
Teachable Moment | 
Laura Perry Fernandez, MD; Jillian Catalanotti, MD, MPH; James Croffoot, MD
JAMA Intern Med. 2016;176(5):590-591. doi:10.1001/jamainternmed.2016.0348.

JAMA Oncology | 
Research Letter | 
Firas Abdollah, MD; Maxine Sun, MPH; Jesse D. Sammon, DO; et al.
JAMA Oncol. 2016;2(4):543-545. doi:10.1001/jamaoncol.2015.5871.

JAMA Oncology | 
Original Investigation |  Open Access
Nicholas D. James, PhD, FRCR, FRCP; Sarah J. Pirrie, MSc; Ann M. Pope, PhD; et al.
JAMA Oncol. 2016;2(4):493-499. doi:10.1001/jamaoncol.2015.5570.
Includes: Supplemental Content

JAMA Oncology | 
Editorial | 
Michael Kolinsky, BSc, MD; Pasquale Rescigno, MD; Johann S. de Bono, MB, ChB, MSc, FRCP, PhD, FMedSci
JAMA Oncol. 2016;2(4):437-438. doi:10.1001/jamaoncol.2015.4918.

JAMA Oncology | 
Invited Commentary | 
Saroj Niraula, MBBS, MD, MSc; Ian F. Tannock, MD, PhD
JAMA Oncol. 2016;2(4):461-462. doi:10.1001/jamaoncol.2015.4682.

JAMA Oncology | 
Original Investigation | 
Dawn L. Hershman, MD, MS; Joseph M. Unger, PhD; Jason D. Wright, MD; et al.
JAMA Oncol. 2016;2(4):453-461. doi:10.1001/jamaoncol.2015.4655.
Includes: Supplemental Content

JAMA Oncology | 
Original Investigation | 
Maxine Sun, MPH; Toni K. Choueiri, MD; Ole-Petter R. Hamnvik, MD; et al.
JAMA Oncol. 2016;2(4):500-507. doi:10.1001/jamaoncol.2015.4917.

JAMA Oncology | 
Invited Commentary | 
Sean E. McGuire, MD, PhD
JAMA Oncol. 2016;2(4):480-481. doi:10.1001/jamaoncol.2015.4952.

JAMA Oncology | 
Invited Commentary | 
Marianne Schmid, MD; Felix K.-H. Chun, MD; Quoc-Dien Trinh, MD
JAMA Oncol. 2016;2(4):470. doi:10.1001/jamaoncol.2015.5172.

JAMA Oncology | 
Original Investigation | 
Joseph R. Evans, MD, PhD; Shuang G. Zhao, MD; S. Laura Chang, PhD; et al.
JAMA Oncol. 2016;2(4):471-480. doi:10.1001/jamaoncol.2015.4955.
Includes: Supplemental Content

JAMA Internal Medicine | 
Research Letter | 
Michael E. Zavaski, MD; Christian P. Meyer, MD; Jesse D. Sammon, DO; et al.
JAMA Intern Med. 2016;176(4):546-547. doi:10.1001/jamainternmed.2015.7901.

JAMA Oncology | 
Invited Commentary | 
Anthony V. D’Amico, MD, PhD
JAMA Oncol. 2016;2(3):357-358. doi:10.1001/jamaoncol.2015.4342.

JAMA Oncology | 
Original Investigation |  Open Access
Nicholas D. James, BSc, MBBS, PhD, FRCP, FRCR; Melissa R. Spears, MSc, BSc; Noel W. Clarke, MBBS, FRCS(Eng), ChM(Manch), FRCS(Urol); et al.
JAMA Oncol. 2016;2(3):348-357. doi:10.1001/jamaoncol.2015.4350.
Includes: Supplemental Content

JAMA | 
News From the Centers for Disease Control and Prevention | 
JAMA. 2016;315(6):550. doi:10.1001/jama.2016.0102.

JAMA | 
Original Investigation |  FREE
Lorelei A. Mucci, ScD, MPH; Jacob B. Hjelmborg, PhD; Jennifer R. Harris, PhD; et al.
JAMA. 2016;315(1):68-76. doi:10.1001/jama.2015.17703.
Includes: CME, Supplemental Content

JAMA Oncology | 
Invited Commentary | 
Otis W. Brawley, MD, MACP
JAMA Oncol. 2016;2(1):93-94. doi:10.1001/jamaoncol.2015.3615.

JAMA Oncology | 
Original Investigation | 
Marianne Schmid, MD; Christian P. Meyer, MD; Gally Reznor, MS; et al.
JAMA Oncol. 2016;2(1):85-93. doi:10.1001/jamaoncol.2015.3384.
Includes: Supplemental Content

JAMA Oncology | 
Invited Commentary | 
Christopher J. Sweeney, MBBS
JAMA Oncol. 2015;1(9):1270-1271. doi:10.1001/jamaoncol.2015.3005.

JAMA Oncology | 
Original Investigation | 
Sindy Magnan, MD, MSc, FRCPC; Ryan Zarychanski, MD, MSc, FRCPC; Laurie Pilote, MD; et al.
JAMA Oncol. 2015;1(9):1261-1269. doi:10.1001/jamaoncol.2015.2895.
Includes: Supplemental Content

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Original Investigation  | 
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered A Post hoc Analysis of the Mainsail Study
Ellen S. de Morrée, MSc; Nicholas J. Vogelzang, MD; Daniel P. Petrylak, MD; et al.
JAMA Oncology
Viewpoint  | 
Intermittent Androgen Deprivation Primum Non Nocere—“First Do NO Harm”
Maha Hussain, MD; Mario Eisenberger, MD
JAMA Oncology
Viewpoint  | 
Intermittent Androgen Deprivation Therapy—An Important Treatment Option for Prostate Cancer
Laurence Klotz, MD, FRCSC, CM; Celestia S, Higano, MD
JAMA Oncology
Research Letter  | 
Prostate Cancer Incidence Rates 2 Years After the US Preventive Services Task Force Recommendations Against Screening
Ahmedin Jemal, DVM, PhD; Jiemin Ma, PhD; Rebecca Siegel, MPH; et al.